This Evaluation of PD-L1 expression in vulvar cancer_DATA_README.txt file was generated on 2022-09-07 by Dr.Ghada Sahraoui GENERAL INFORMATION 1. Title of Dataset: Data from: Evaluation of PD-L1 expression in vulvar cancer 2. Author Information Corresponding Investigator Name: Dr Ghada Sahraoui Institution: Department of Pathology, Salah Azaiez Institute, Tunis, Tunisia Address: bab saadoun, 1006, Tunis, Tunisia Email: ghada_sahraoui@yahoo.com Co-investigator Name: Mrs Maroua Manai Institution: Human Genetics Laboratory LR99ES10, University of medecine of Tunis, University of Tunis El Manar, Tunis, Tunisia Email: marwa.manai@northwestern.edu Co-investigator Name: Dr Rahma Yaiche Institution: Department of Pathology, Salah Azaiez Institute, Tunis, Tunisia Email: rama.yae88@gmail.com Co-investigator Name: Dr Lamia Charfi Institution: Department of Pathology, Salah Azaiez Institute, Tunis, Tunisia Email: lamiacharfi@gmail.com Co-investigator Name: Dr Montassar Ghalleb Institution: Surgical Oncology Department, Salah Azaiez Institute, Tunis, Tunisia Email: montassar.ghalleb@fmt.utm.tn Co-investigator Name: Mrs Hayet Douik Institution: Research Laboratory LR21SP01, Salah Azaiez Institute, Tunis, Tunisia Email: htdouik@yahoo.fr Co-investigator Name: Dr Karima Mrad Institution: Department of Pathology, Salah Azaiez Institute, Tunis, Tunisia Email: karimamrad@ymail.com Co-investigator Name: Dr Raoudha Doghri Institution: Department of Pathology, Salah Azaiez Institute, Tunis, Tunisia Email: raoudha.doghri@gmail.com 3. Date of data collection: 2008-2021 4. Geographic location of data collection: Salah Azaiez Institute, Tunis, Tunisia 5. Information about funding sources that supported the collection of the data: no fundings were received to assist with the collection of the data. 6. Recommended citation for this dataset: Sahraoui G et al. (2022), Data for the article: Evaluation of PD-L1 expression in vulvar cancer DATA & FILE OVERVIEW 1. Description of dataset These data were generated to investigate the expression profile of PD-L1 in vulvar cancer using immunohistochemistry and to correlate it with survival rates. 2. File List: File 1 Name: TMA Protocol data. xlsx File 1 Description: this table contains all the date of the TMA protocol. File 2 Name: Figure (1) .JPEG File 2 Description:(x400) PD-L1 Immunostaining of 60% of tumor cells with moderate expression intensity File 3 Name: Figure (2) .JPEG File 3 Description:(x400) PD-L1 Immunostaining of 30% of tumor cells with high expression intensity File 4 Name: Figure (3).JPEG File 4 Description:(x400) PD-L1 Immunostaining of 15% of tumor cells with moderate expression intensity File 5 Name: Figure (4).JPEG File 5 Description:(x400) PD-L1 Negative immunostaining for tumor cells and lymphocytes File 6 Name: Figure (5).JPEG File 6 Description:(x400) PD-L1 Immunostaining of 10% of lymphocytes with moderate expression intensity File 7 Name: Figure (6).JPEG File 7 Description:(x400) PD-L1 Immunostaining of 30% of tumor cells with moderate expression intensity and 60% of lymphocytes with high expression intensity File 8 Name: Table (1) raw clinicopathological data.xlsx File 8 Description: clinicopathological data collected from 55 patients who were diagnosed with vulvar cancer with results of PD-L1 expression. File 9 Name: Figure (7).JPEG File 9 Description: Overall survival for women treated for Squamous Cell Carcinoma of Vulva, according to the Kaplan-Meier method File 10 Name: Figure (8). JPEG File 10 Description: Recurrence-free survival for women treated for Squamous Cell Carcinoma of Vulva, according to the Kaplan-Meier method METHODOLOGICAL INFORMATION A total of 54 cases of vulvar cancer samples were retrieved surgically and one by biopsy. Immunohistochemical analysis was performed using an automaton (BOND-MAX, Leica Biosystems, Melbourne Pty Ltd). Immunohistochemical steps of the protocol were performed with EnVision FLEX visualization system (Dako) for 60min. Primary antibody used was PD-L1, monoclonal Mouse (clone 22C3, Isotype: IgG1 kappa, Ref M3653, Batchcode 11146263). The concentration required was 1/50 and manufacturing company was Dako (North America INC, 6392 Via Real, Carpinteria CA, 93013, USA Immunohistochemistry samples were imaged using Olympus BX51 microscope with camera(olympus U-TV0.63XC SN 1H50935 T7 TOKYO, JAPAN) with a 40x oil objective. DATA-SPECIFIC INFORMATION FOR: Table (1) raw clinicopathological data.xlsx 1. Number of variables: 17 2. Number of cases/rows: 55 3. Variable List: patient: patient ID number included in cohort age of diagnosis: Age at the time of diagnosis symptoms (0= incidental discovery, 1= vulvar pruritus, 2= pelvic pain with mictional burning) Sample type (0=surgical sections, 1= biopsy) tumor location (0=lateral, 1=medial, 2=both) tumor focality (0=unifocal, 1=multifocal Tumor size(mm) ulceration (0=absent, 1=present) Histological type (0= squamous cell carcinoma, 1=other) Immunostaining of tumor cells (0=negative, 1=positive) Immunostaining of lymphocytes (0=negative, 1=positive) Percentage of f PD-L1 (%) Intensity of PD-L1 (0= weak, 1=moderate, 2=strong) Surgical margins (0= involved, 1= free of invasion) Inguinal dissection (0= no, 1=yes) Lymph node metastasis (0= absent, 1=present) reccurence at follow-up (0=no, 1=yes) 4. Missing data codes: N/A. 5. Abbreviations used: PD-L1: programmed cell death 1 ligand TMA: Tissue MicroArray OS: Overall Survival RFS: Recurrence Free Survival